NDAOPHTHALMICSOLUTION/DROPS
Approved
Mar 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
VISINE L.R. (oxymetazoline hydrochloride) by PharmaIN. Approved for rosacea, blepharophimosis. First approved in 1989.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VISINE L.R. is an ophthalmic solution containing oxymetazoline hydrochloride, a sympathomimetic amine used to treat rosacea and blepharophimosis. The drug works as a vasoconstrictor, reducing ocular vasodilation and associated symptoms through alpha-adrenergic receptor stimulation.
LOE Approaching
Product is approaching loss of exclusivity with modest competitive pressure (30/100), indicating declining team investment and consolidation opportunities in the ophthalmic space.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on VISINE L.R. at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.